We are a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. Our company was founded on the premise that the upper nasal cavity can be […]

We are a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which we are able to genetically select patients we believe will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. We have in-licensed product candidates, each with a differentiated profile […]

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our product pipeline is focused on rare gastrointestinal, or GI, disorders. Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like […]

  Our mission is to empower financial institutions to grow confidently, adapt quickly and build thriving digital communities. Alkami is a cloud-based digital banking platform. We inspire and empower community, regional and super-regional financial institutions (“FIs”) to compete with large, technologically advanced and well-resourced banks in the United States. Our solution, the Alkami Platform, allows […]

Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). We are developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy […]

(Note: NASDAQ announced late Tuesday afternoon, April 13, 2021, that $250 is the reference price for the Coinbase Global direct listing. The stock is expected to start trading on NASDAQ on Wednesday, April 14, 2021. This is NOT a traditional IPO. There are no underwriters. Goldman Sachs, J.P. Morgan, Allen & Co. and Citigroup are […]

We are a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation, or MV, which is the standard of care today for the treatment of respiratory failure. Although it may be lifesaving, MV is associated with increased […]

We are a blank check company incorporated on October 28, 2020 as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination. We have […]

(Note: This is a blank-check company’s IPO of Class A ordinary shares and NOT units, which make up the typical SPAC IPO.) We intend to focus on the technology industry and the Innovation Economy. This is a newly organized blank-check company created and led by Kevin Hartz, the co-founder of EventBrite (NYSE: EB), which went […]

Our Mission:  Energize everyday life. We are a consumer tech company, known as Energy Monster, that provides mobile device charging service through an extensive online and offline network. We are the largest mobile device charging service provider in China in terms of gross revenues in 2020, according to the iResearch Report. We provide service through our […]